PTC-209 is a small molecule inhibitor primarily investigated for its potential in cancer therapy, specifically targeting cancer stem cells (CSCs). It has shown promise in suppressing tumor growth and recurrence by inhibiting the BMI-1 protein, a key regulator in stem cell self-renewal and survival. This makes PTC-209 particularly effective in preclinical models of colorectal cancer, where BMI-1-positive cancer stem cells are responsible for tumor initiation and resistance to conventional treatments. The compound has demonstrated the ability to reduce the population of cancer stem cells, thereby enhancing the efficacy of chemotherapy and radiation. It is also being explored in other BMI-1-dependent cancers such as head and neck squamous cell carcinoma and certain types of leukemia. Due to its selective action on cancer stem cells without significant toxicity to normal cells, PTC-209 represents a strategic approach in developing targeted therapies aimed at preventing relapse and improving long-term outcomes in cancer patients.